Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence
Authors:
- Jimi OlaghereJOJimi Olaghere
- David A. WilliamsDWDavid A. Williams
- Jeremy FarrarJFJeremy Farrar
- Hildegard BüningHBHildegard Büning
- Cecelia CalhounCCCecelia Calhoun
- Tony HoTHTony Ho
- Maneesha S. InamdarMIManeesha S. Inamdar
- David LiuDLDavid Liu
- Julie MakaniJMJulie Makani
- Kwasi NyarkoKNKwasi Nyarko
- Sol RuizSRSol Ruiz
- John TisdaleJTJohn Tisdale
Top Cited Papers
Open Access
- 20 March 2025
- journal article
- conference paper
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 758
Abstract
On 4 September 2024, the Reagan-Udall Foundation for the FDA (FDA Foundation) in collaboration with the Food and Drug Administration (FDA) and the Gates Foundation hosted a workshop titled “Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence”. The event brought together a diverse group of experts, including international regulatory bodies, regulated industries, healthcare professionals, patients, academic researchers and global health advocates, to discuss the rapid advancements in gene therapy and the pressing need for equitable access in low-and middle-income countries (LMICs), with sickle cell disease (SCD) serving as the model disorder for the discussions. Although there has been significant progress in gene therapy, such as breakthroughs in clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies and FDA-approved therapies, access to these therapies remain limited in underresourced regions. The workshop addressed critical challenges, including the high cost of therapies, regulatory gaps and barriers and ethical concerns regarding informed consent and public engagement in LMICs. This paper highlights the critical discussion points from the workshop with a focus on exploring strategies for global regulatory convergence, the role of international collaborations and the potential pathways to making gene therapies affordable and accessible to all.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-073968)
This publication has 24 references indexed in Scilit:
- CAR T Cells and T-Cell Therapies for CancerJAMA, 2024
- Adeno-Associated Virus Vectors—a Target of Cellular and Humoral Immunity—are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and ImmunotherapiesHuman Gene Therapy, 2024
- Gene therapy for rare haematological and neurometabolic paediatric diseasesGlobal Pediatrics, 2024
- A new age of precision gene therapyThe Lancet, 2023
- In Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid NanoparticlesNano Letters, 2023
- Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and IndiaMolecular Therapy, 2022
- Search-and-replace genome editing without double-strand breaks or donor DNANature, 2019
- Societal challenges of precision medicine: Bringing order to chaosEuropean Journal of Cancer, 2017
- Prevailing Public Perceptions of the Ethics of Gene TherapyHuman Gene Therapy, 2014
- Balancing Personalized Medicine and Personalized CareAcademic Medicine, 2013